Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

NCT00704730 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
330
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Exelixis